A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Biomarker; Therapeutic Use
- 29 Jun 2018 Planned primary completion date changed from 1 Jun 2015 to 1 Nov 2018.
- 10 Jun 2017 Biomarkers information updated
- 14 Dec 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.